Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia
Identifieur interne : 001718 ( Istex/Corpus ); précédent : 001717; suivant : 001719Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia
Auteurs : A. WaladkhaniSource :
- European Journal of Cancer Care [ 0961-5423 ] ; 2004-09.
English descriptors
- KwdEn :
Abstract
Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.
Url:
DOI: 10.1111/j.1365-2354.2004.00503.x
Links to Exploration step
ISTEX:2D0503325A4D3C658F722C331719FB85571CE860Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title><author><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name><affiliation><mods:affiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: waladkha@uni‐trier.de</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2D0503325A4D3C658F722C331719FB85571CE860</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1365-2354.2004.00503.x</idno><idno type="url">https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001718</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001718</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title><author><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name><affiliation><mods:affiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: waladkha@uni‐trier.de</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Cancer Care</title><idno type="ISSN">0961-5423</idno><idno type="eISSN">1365-2354</idno><imprint><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-09">2004-09</date><biblScope unit="volume">13</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="371">371</biblScope><biblScope unit="page" to="379">379</biblScope></imprint><idno type="ISSN">0961-5423</idno></series><idno type="istex">2D0503325A4D3C658F722C331719FB85571CE860</idno><idno type="DOI">10.1111/j.1365-2354.2004.00503.x</idno><idno type="ArticleID">ECC503</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0961-5423</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>chemotherapy</term><term>filgrastim</term><term>granulocyte colony‐stimulating factors</term><term>neutropenia</term><term>pegfilgrastim</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>A.‐R. WALADKHANI bsc, phd</name><affiliations><json:string>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany</json:string><json:string>E-mail: waladkha@uni‐trier.de</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>neutropenia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>chemotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>granulocyte colony‐stimulating factors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>filgrastim</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pegfilgrastim</value></json:item></subject><articleId><json:string>ECC503</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.</abstract><qualityIndicators><score>7.24</score><pdfVersion>1.4</pdfVersion><pdfPageSize>595 x 782 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1225</abstractCharCount><pdfWordCount>5030</pdfWordCount><pdfCharCount>33351</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>145</abstractWordCount></qualityIndicators><title>Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title><refBibs><json:item><host><author></author><title>Amgen (2002) Neulasta™ (Pegfilgrastim) Summary of Product Characteristics.Amgen Europe BV, The Netherlands.</title></host></json:item><json:item><author><json:item><name>P. Bailon</name></json:item><json:item><name>W. Berthold</name></json:item></author><host><volume>1</volume><pages><last>356</last><first>352</first></pages><author></author><title>Pharmaceutical Science & Technology Today</title></host><title>Polyethylene glycol‐conjugated pharmaceutical proteins</title></json:item><json:item><author><json:item><name>L. Balducci</name></json:item><json:item><name>J. Yates</name></json:item></author><host><volume>14</volume><pages><last>227</last><first>221</first></pages><author></author><title>Oncology</title></host><title>General guidelines for the management of older patients with cancer</title></json:item><json:item><author><json:item><name>C. Bedell</name></json:item></author><host><volume>7</volume><pages><last>58</last><first>55</first></pages><author></author><title>Clinical Journal of Oncology Nursing</title></host><title>Pegfilgrastim for chemotherapy‐induced neutropenia</title></json:item><json:item><author><json:item><name>C. Bedell</name></json:item><json:item><name>F.A. Holmes</name></json:item><json:item><name>M. Green</name></json:item><json:item><name>J. Crawford</name></json:item><json:item><name>B.D. Liang</name></json:item></author><host><volume>29</volume><pages><first>188</first></pages><author></author><title>Oncology Nursing Forum</title></host><title>Pegfilgrastim: an investigational sustained‐duration G‐CSF with once‐per‐cycle dosing and safety and efficacy equivalent to those of filgrastim</title></json:item><json:item><author><json:item><name>G.P. Bodey</name></json:item><json:item><name>M. Buckley</name></json:item><json:item><name>Y.‐S. Sathe</name></json:item><json:item><name>E.J. Freireich</name></json:item></author><host><volume>64</volume><pages><last>340</last><first>328</first></pages><author></author><title>Annals of Internal Medicine</title></host><title>Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia</title></json:item><json:item><author><json:item><name>G. Bonadonna</name></json:item><json:item><name>P. Valagussa</name></json:item><json:item><name>A. Moliterni</name></json:item><json:item><name>M. Zambetti</name></json:item><json:item><name>C. Brambilla</name></json:item></author><host><volume>332</volume><pages><last>906</last><first>901</first></pages><author></author><title>New England Journal of Medicine</title></host><title>Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node‐positive breast cancer. The results of 20 years of follow‐up</title></json:item><json:item><author><json:item><name>C. Cappozzo</name></json:item></author><host><volume>29</volume><pages><first>186</first></pages><author></author><title>Oncology Nursing Forum</title></host><title>Predicting the risk of neutropenic complications in patients treated with adjuvant chemotherapy for early‐stage breast cancer</title></json:item><json:item><author><json:item><name>J. Chang</name></json:item></author><host><volume>36</volume><pages><last>14</last><first>11</first></pages><author></author><title>European Journal of Cancer</title></host><title>Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer</title></json:item><json:item><host><author></author><title>Crawford J., Garst J., Lee M., Schnell F., Belani C.P., Hill B., Lockbaum P. & Schwab G. (2000) A phase II multicycle trial of pegfilgrastim compared to filgrastim after myelosuppressive chemotherapy. International Association for the Study of Lung Cancer, 9th World Conference on Lung Cancer, September 2000, Tokyo, Japan. p. 922[Abstract].</title></host></json:item><json:item><author><json:item><name>J. Crawford</name></json:item><json:item><name>H. Ozer</name></json:item><json:item><name>R. Stoller</name></json:item><json:item><name>D. Johnson</name></json:item><json:item><name>G. Lyman</name></json:item><json:item><name>I. Tabbara</name></json:item><json:item><name>M. Kris</name></json:item><json:item><name>J. Grous</name></json:item><json:item><name>V. Picozzi</name></json:item><json:item><name>G. Rausch</name></json:item><json:item><name>R. Smith</name></json:item><json:item><name>W. Gradisher</name></json:item><json:item><name>A. Yahan</name></json:item><json:item><name>M. Vincent</name></json:item><json:item><name>M. Stewart</name></json:item><json:item><name>J. Glaspy</name></json:item></author><host><volume>325</volume><pages><last>170</last><first>164</first></pages><author></author><title>New England Journal of Medicine</title></host><title>Reduction by granulocyte colony‐stimulating factor of fever and neutropenia induced by chemotherapy in patients with small‐cell lung cancer</title></json:item><json:item><author><json:item><name>C. Delgado</name></json:item><json:item><name>G.E. Francis</name></json:item><json:item><name>D. Fisher</name></json:item></author><host><volume>9</volume><pages><last>304</last><first>249</first></pages><author></author><title>Critical Reviews in Therapeutic Drug Carrier Systems</title></host><title>The uses and properties of PEG‐linked proteins</title></json:item><json:item><author><json:item><name>J.L. Gabrilove</name></json:item><json:item><name>A. Jakubowski</name></json:item><json:item><name>H. Scher</name></json:item><json:item><name>C. Sternberg</name></json:item><json:item><name>G. Wong</name></json:item><json:item><name>J. Grous</name></json:item><json:item><name>A. Yagoda</name></json:item><json:item><name>K. Fain</name></json:item><json:item><name>M. Moore</name></json:item><json:item><name>B. Clarkson</name></json:item><json:item><name>H.F. Oettgen</name></json:item><json:item><name>K. Alton</name></json:item><json:item><name>K. Welte</name></json:item><json:item><name>L. Souza</name></json:item></author><host><volume>318</volume><pages><last>1422</last><first>1414</first></pages><author></author><title>New England Journal of Medicine</title></host><title>Effect of granulocyte colony‐stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional‐cell carcinoma of the urothelium</title></json:item><json:item><author><json:item><name>S. George</name></json:item><json:item><name>F. Yunus</name></json:item><json:item><name>B.‐B. Yang</name></json:item><json:item><name>J. Hackett</name></json:item><json:item><name>T. Neumann</name></json:item><json:item><name>B. Liang</name></json:item></author><host><volume>98</volume><pages><first>3700</first></pages><author></author><title>Blood</title></host><title>Pharmacokinetic profiles of fixed dose single pegfilgrastim administration in patients with non‐Hodgkin's lymphoma</title></json:item><json:item><author><json:item><name>M.D. Green</name></json:item><json:item><name>H. Koelbl</name></json:item><json:item><name>J. Baselga</name></json:item><json:item><name>A. Galid</name></json:item><json:item><name>V. Guillem</name></json:item><json:item><name>P. Gascon</name></json:item><json:item><name>S. Siena</name></json:item><json:item><name>R.I. Lalisang</name></json:item><json:item><name>H. Samonigg</name></json:item><json:item><name>M.R. Clemens</name></json:item><json:item><name>V. Zoni</name></json:item><json:item><name>B.C. Liang</name></json:item><json:item><name>J. Renwick</name></json:item><json:item><name>M.J. Piccart</name></json:item></author><host><volume>14</volume><pages><last>35</last><first>29</first></pages><author></author><title>Annals of Oncology</title></host><title>A randomized, double‐blind, multicenter, phase 3 study of fixed‐dose, single‐administration pegfilgrastim vs daily filgrastim in patients receiving myelosuppressive chemotherapy</title></json:item><json:item><author><json:item><name>A. Grigg</name></json:item><json:item><name>P. Solal‐Céligny</name></json:item><json:item><name>P. Hoskin</name></json:item></author><host><volume>44</volume><pages><last>1508</last><first>03</first></pages><author></author><title>Leukemia & Lymphoma</title></host><title>Open‐label, randomised study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non‐Hodgkin's lymphoma</title></json:item><json:item><author><json:item><name>N.A. Hayes</name></json:item></author><host><volume>28</volume><pages><last>16</last><first>11</first></pages><author></author><title>Oncology Nursing Forum</title></host><title>Analyzing current practice patterns: lessons from Amgen's Project ChemoInsight®</title></json:item><json:item><author><json:item><name>J. Hinton</name></json:item><json:item><name>B. Bilodeau</name></json:item><json:item><name>B. Ford</name></json:item><json:item><name>D. Sarnacki</name></json:item><json:item><name>C. Wood</name></json:item><json:item><name>M. Gerbracht</name></json:item></author><host><volume>29</volume><pages><first>190</first></pages><author></author><title>Oncology Nursing Forum</title></host><title>Delivering full planned dose on time (PDOT) chemotherapy (CT) while lowering the incidence of febrile neutropenia (FN) hospitalisations in high risk breast cancer patients (BCP)</title></json:item><json:item><author><json:item><name>F.A. Holmes</name></json:item><json:item><name>S.E. Jones</name></json:item><json:item><name>J. O'Shaughnessy</name></json:item><json:item><name>S. Vukelja</name></json:item><json:item><name>T. George</name></json:item><json:item><name>M. Savin</name></json:item><json:item><name>D. Richards</name></json:item><json:item><name>J. Glaspy</name></json:item><json:item><name>L. Meza</name></json:item><json:item><name>G. Cohen</name></json:item><json:item><name>M. Dhami</name></json:item><json:item><name>D.R. Budman</name></json:item><json:item><name>J. Hackett</name></json:item><json:item><name>M. Brassard</name></json:item><json:item><name>B.B. Yang</name></json:item><json:item><name>B.C. Liang</name></json:item></author><host><volume>13</volume><pages><last>909</last><first>903</first></pages><author></author><title>Annals of Oncology</title></host><title>Comparable efficacy and safety profiles of once‐per‐cycle pegfilgrastim and daily injection filgrastim in chemotherapy‐induced neutropenia: a multicenter dose‐finding study in women with breast cancer</title></json:item><json:item><author><json:item><name>F.A. Holmes</name></json:item><json:item><name>J.A. O'Shaughnessy</name></json:item><json:item><name>S. Vukelja</name></json:item><json:item><name>S.E. Jones</name></json:item><json:item><name>J. Shogan</name></json:item><json:item><name>M. Savin</name></json:item><json:item><name>J. Glaspy</name></json:item><json:item><name>M. Moore</name></json:item><json:item><name>L. Meza</name></json:item><json:item><name>I. Wiznitzer</name></json:item><json:item><name>T.A. Neumann</name></json:item><json:item><name>L.R. Hill</name></json:item><json:item><name>B.C. Liang</name></json:item></author><host><volume>20</volume><pages><last>731</last><first>727</first></pages><author></author><title>Journal of Clinical Oncology</title></host><title>Blinded, randomized, multicenter study to evaluate single administration of pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high‐risk stage II or stage III/IV breast cancer</title></json:item><json:item><author><json:item><name>W.T. Hughes</name></json:item><json:item><name>D. Armstrong</name></json:item><json:item><name>G.P. Bodey</name></json:item><json:item><name>A.E. Brown</name></json:item><json:item><name>J.E. Edwards</name></json:item><json:item><name>R. Feld</name></json:item><json:item><name>P. Pizzo</name></json:item><json:item><name>K.V. Rolston</name></json:item><json:item><name>J.L. Shenep</name></json:item><json:item><name>L.S. Young</name></json:item></author><host><volume>25</volume><pages><last>573</last><first>551</first></pages><author></author><title>Clinical Infectious Diseases</title></host><title>1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever</title></json:item><json:item><author><json:item><name>T. Intragumtornchai</name></json:item><json:item><name>J. Sutheesophon</name></json:item><json:item><name>P. Sutcharitchan</name></json:item><json:item><name>D. Swasdikul</name></json:item></author><host><volume>37</volume><pages><last>360</last><first>351</first></pages><author></author><title>Leukemia & Lymphoma</title></host><title>A predictive model for life‐threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non‐Hodgkin's lymphoma</title></json:item><json:item><author><json:item><name>E. Johnston</name></json:item><json:item><name>J. Crawford</name></json:item><json:item><name>S. Blackwell</name></json:item><json:item><name>T. Bjurstrom</name></json:item><json:item><name>P. Lockbaum</name></json:item><json:item><name>L. Roskos</name></json:item><json:item><name>B.B. Yang</name></json:item><json:item><name>S. Gardner</name></json:item><json:item><name>M.A. Miller‐Messana</name></json:item><json:item><name>D. Shoemaker</name></json:item><json:item><name>J. Garst</name></json:item><json:item><name>G. Schwab</name></json:item></author><host><volume>18</volume><pages><last>2528</last><first>2522</first></pages><author></author><title>Journal of Clinical Oncology</title></host><title>Randomized, dose‐escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy</title></json:item><json:item><author><json:item><name>L.W. Kwak</name></json:item><json:item><name>J.H. Halpern</name></json:item><json:item><name>R.A. Olshen</name></json:item><json:item><name>S.J. Horning</name></json:item></author><host><volume>8</volume><pages><last>977</last><first>963</first></pages><author></author><title>Journal of Clinical Oncology</title></host><title>Prognostic significance of actual dose intensity in diffuse large‐cell lymphoma: results of a tree‐structure survival analysis</title></json:item><json:item><author><json:item><name>R.C.F. Leonard</name></json:item><json:item><name>D. Miles</name></json:item><json:item><name>R. Thomas</name></json:item><json:item><name>F. Nussey</name></json:item></author><host><volume>89</volume><pages><last>2068</last><first>2062</first></pages><author></author><title>British Journal of Cancer</title></host><title>The impact of delivering planned adjuvant chemotherapy; UK audit of primary breast cancer patients</title></json:item><json:item><author><json:item><name>J.L. Misset</name></json:item><json:item><name>V. Dieras</name></json:item><json:item><name>G. Gruia</name></json:item><json:item><name>H. Bourgeois</name></json:item><json:item><name>E. Cvltkovic</name></json:item><json:item><name>S. Kalla</name></json:item><json:item><name>L. Bozec</name></json:item><json:item><name>P. Beuzeboc</name></json:item><json:item><name>C. Jasmin</name></json:item><json:item><name>J.P. Aussel</name></json:item><json:item><name>A. Riva</name></json:item><json:item><name>N. Azli</name></json:item><json:item><name>P. Pouillart</name></json:item></author><host><volume>10</volume><pages><last>560</last><first>553</first></pages><author></author><title>Annals of Oncology</title></host><title>Dose‐finding study of docetaxel and doxorubicin in first‐line treatment of patients with metastatic breast cancer</title></json:item><json:item><author><json:item><name>G. Molineux</name></json:item><json:item><name>O. Kinstler</name></json:item><json:item><name>B. Briddell</name></json:item><json:item><name>C. Hartley</name></json:item><json:item><name>P. McElroy</name></json:item><json:item><name>P. Kerzic</name></json:item><json:item><name>W. Sutherland</name></json:item><json:item><name>G. Stoney</name></json:item><json:item><name>B. Kern</name></json:item><json:item><name>F.A. Fletcher</name></json:item><json:item><name>A. Cohen</name></json:item><json:item><name>E. Korach</name></json:item><json:item><name>T. Ulich</name></json:item><json:item><name>I. McNiece</name></json:item><json:item><name>P. Lockbaum</name></json:item><json:item><name>M.A. Miller‐Messana</name></json:item><json:item><name>S. Gardner</name></json:item><json:item><name>T. Hunt</name></json:item><json:item><name>G. Schwab</name></json:item></author><host><volume>27</volume><pages><last>1734</last><first>1724</first></pages><author></author><title>Experimental Hematology</title></host><title>A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans</title></json:item><json:item><author><json:item><name>N.A. Nicola</name></json:item></author><host><volume>8</volume><pages><last>140</last><first>134</first></pages><author></author><title>Immunology Today</title></host><title>Why do hemopoietic growth factor receptors interact with each other?</title></json:item><json:item><author><json:item><name>K.R. Reddy</name></json:item></author><host><volume>34</volume><pages><last>923</last><first>915</first></pages><author></author><title>Annals of Pharmacotherapy</title></host><title>Controlled‐release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs</title></json:item><json:item><author><json:item><name>L.K. Roskos</name></json:item><json:item><name>B. Yank</name></json:item><json:item><name>G. Schwab</name></json:item><json:item><name>P. Lockbaum</name></json:item><json:item><name>G. Molineux</name></json:item><json:item><name>E. Johnston</name></json:item><json:item><name>J. Crawford</name></json:item><json:item><name>K. Khoo</name></json:item><json:item><name>E.N. Cheung</name></json:item></author><host><volume>92</volume><pages><first>2085</first></pages><author></author><title>Blood</title></host><title>A cytokinetic model of r‐metHuG‐CSF‐SD/01 (SD/01) mediated granulopoiesis and the ‘self‐regulation’ of SD/01 elimination of non‐small‐cell lung cancer (NSCLC) patients</title></json:item><json:item><author><json:item><name>S. Siena</name></json:item><json:item><name>M.J. Piccart</name></json:item><json:item><name>F.A. Holmes</name></json:item><json:item><name>J. Glaspy</name></json:item><json:item><name>J. Hackett</name></json:item><json:item><name>J. Renwick</name></json:item></author><host><volume>10</volume><pages><last>724</last><first>715</first></pages><author></author><title>Oncology Reports</title></host><title>A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II–IV breast cancer</title></json:item><json:item><author><json:item><name>J.H. Silber</name></json:item><json:item><name>M. Fridman</name></json:item><json:item><name>R.S. DiPaola</name></json:item><json:item><name>M.H. Erder</name></json:item><json:item><name>M.V. Pauly</name></json:item><json:item><name>K.R. Fox</name></json:item></author><host><volume>16</volume><pages><last>2400</last><first>2392</first></pages><author></author><title>Journal of Clinical Oncology</title></host><title>First‐cycle blood counts and subsequent neutropenia, dose reduction, or delay in early‐stage breast cancer therapy</title></json:item><json:item><author><json:item><name>V. Trillet‐Lenoir</name></json:item><json:item><name>J. Green</name></json:item><json:item><name>C. Manegold</name></json:item><json:item><name>J. Von Pawel</name></json:item><json:item><name>U. Gatzemeier</name></json:item><json:item><name>B. Lebeau</name></json:item><json:item><name>A. Depierre</name></json:item><json:item><name>P. Johnson</name></json:item><json:item><name>G. Decoster</name></json:item><json:item><name>D. Tomita</name></json:item><json:item><name>C. Ewen</name></json:item></author><host><volume>29A</volume><pages><last>324</last><first>319</first></pages><author></author><title>European Journal of Cancer</title></host><title>Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy</title></json:item><json:item><author><json:item><name>M.E. Vincent</name></json:item><json:item><name>M. Foote</name></json:item><json:item><name>G. Morstyn</name></json:item></author><host><pages><last>50</last><first>33</first></pages><author></author><title>Filgrastim (Royal‐Methug‐CSF) in Clinical Practice</title></host><title>Pharmacology of filgrastim (r‐metHuG‐CSF)</title></json:item><json:item><author><json:item><name>J.M. Vose</name></json:item><json:item><name>M. Crump</name></json:item><json:item><name>H. Lazarus</name></json:item><json:item><name>C. Emmanouilides</name></json:item><json:item><name>D. Schenkein</name></json:item><json:item><name>J. Moore</name></json:item><json:item><name>S. Frankel</name></json:item><json:item><name>I. Flinn</name></json:item><json:item><name>W. Lovelace</name></json:item><json:item><name>J. Hackett</name></json:item><json:item><name>B.C. Liang</name></json:item></author><host><volume>21</volume><pages><last>519</last><first>514</first></pages><author></author><title>Journal of Clinical Oncology</title></host><title>Randomized, multicenter, open‐label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma</title></json:item><json:item><author><json:item><name>K. Welte</name></json:item><json:item><name>J. Gabrilove</name></json:item><json:item><name>M.H. Bronchud</name></json:item><json:item><name>E. Platzer</name></json:item><json:item><name>G. Morstyn</name></json:item></author><host><volume>88</volume><pages><last>1929</last><first>1907</first></pages><author></author><title>Blood</title></host><title>Filgrastim (r‐metHuG‐CSF): the first 10 years</title></json:item><json:item><author><json:item><name>B.‐B. Yang</name></json:item><json:item><name>P. Lum</name></json:item><json:item><name>J. Ranwick</name></json:item><json:item><name>B. Liang</name></json:item><json:item><name>T. Neumann</name></json:item><json:item><name>S. Nguyen</name></json:item><json:item><name>L. Roskos</name></json:item></author><host><volume>96</volume><pages><first>4384</first></pages><author></author><title>Proceedings of the American Society of Clinical Oncology</title></host><title>Pharmacokinetic rationale for a fixed‐dose regimen of a sustained‐duration form of filgrastim in cancer patients</title></json:item><json:item><author><json:item><name>P.L. Zinzani</name></json:item><json:item><name>E. Pavone</name></json:item><json:item><name>S. Storti</name></json:item><json:item><name>L. Moretti</name></json:item><json:item><name>P.P. Fattori</name></json:item><json:item><name>L. Guardigni</name></json:item><json:item><name>B. Falini</name></json:item><json:item><name>M. Gobbi</name></json:item><json:item><name>P. Gentilini</name></json:item><json:item><name>V.M. Lauta</name></json:item><json:item><name>M. Bendandi</name></json:item><json:item><name>F. Gherlinzoni</name></json:item><json:item><name>M. Magagnoli</name></json:item><json:item><name>S. Venturi</name></json:item><json:item><name>E. Aitini</name></json:item><json:item><name>M. Tabanelli</name></json:item><json:item><name>G. Leone</name></json:item><json:item><name>V. Liso</name></json:item><json:item><name>S. Tura</name></json:item></author><host><volume>89</volume><pages><last>3979</last><first>3974</first></pages><author></author><title>Blood</title></host><title>Randomized trial with or without granulocyte colony‐stimulating factor as adjunct to induction VNCOP‐B treatment of elderly high‐grade non‐Hodgkin's lymphoma</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>13</volume><publisherId><json:string>ECC</json:string></publisherId><pages><total>9</total><last>379</last><first>371</first></pages><issn><json:string>0961-5423</json:string></issn><issue>4</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1365-2354</json:string></eissn><title>European Journal of Cancer Care</title><doi><json:string>10.1111/(ISSN)1365-2354</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>rehabilitation</json:string><json:string>nursing</json:string><json:string>science</json:string><json:string>oncology</json:string><json:string>health care sciences & services</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>oncology & carcinogenesis</json:string></scienceMetrix></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1111/j.1365-2354.2004.00503.x</json:string></doi><id>2D0503325A4D3C658F722C331719FB85571CE860</id><score>0.49702415</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2004</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title><author xml:id="author-1"><persName><forename type="first">A.‐R.</forename><surname>WALADKHANI</surname></persName><roleName type="degree">bsc, phd</roleName><email>waladkha@uni‐trier.de</email><affiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany</affiliation></author></analytic><monogr><title level="j">European Journal of Cancer Care</title><idno type="pISSN">0961-5423</idno><idno type="eISSN">1365-2354</idno><idno type="DOI">10.1111/(ISSN)1365-2354</idno><imprint><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-09"></date><biblScope unit="volume">13</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="371">371</biblScope><biblScope unit="page" to="379">379</biblScope></imprint></monogr><idno type="istex">2D0503325A4D3C658F722C331719FB85571CE860</idno><idno type="DOI">10.1111/j.1365-2354.2004.00503.x</idno><idno type="ArticleID">ECC503</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>neutropenia</term></item><item><term>chemotherapy</term></item><item><term>granulocyte colony‐stimulating factors</term></item><item><term>filgrastim</term></item><item><term>pegfilgrastim</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2354</doi><issn type="print">0961-5423</issn><issn type="electronic">1365-2354</issn><idGroup><id type="product" value="ECC"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF CANCER CARE">European Journal of Cancer Care</title></titleGroup></publicationMeta><publicationMeta level="part" position="09004"><doi origin="wiley">10.1111/ecc.2004.13.issue-4</doi><numberingGroup><numbering type="journalVolume" number="13">13</numbering><numbering type="journalIssue" number="4">4</numbering></numberingGroup><coverDate startDate="2004-09">September 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="11" status="forIssue"><doi origin="wiley">10.1111/j.1365-2354.2004.00503.x</doi><idGroup><id type="unit" value="ECC503"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="tocHeading1">Research</title></titleGroup><eventGroup><event type="firstOnline" date="2004-08-11"></event><event type="publishedOnlineFinalForm" date="2004-08-11"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-19"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-17"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="371">371</numbering><numbering type="pageLast" number="379">379</numbering></numberingGroup><correspondenceTo>Dr Ali‐Reza Waladkhani, Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Feldstr. 1, 54219 Trier, Germany (e‐mail: <email normalForm="waladkha@uni-trier.de">waladkha@uni‐trier.de</email>).</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ECC.ECC503.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Accepted 26 March 2004</unparsedEditorialHistory><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="3"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="38"></count><count type="wordTotal" number="5291"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title><title type="shortAuthors">WALADKHANI</title><title type="short">Pegfilgrastim in chemotherapy‐induced neutropenia</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>A.‐R.</givenNames><familyName>WALADKHANI</familyName><degrees> bsc, phd </degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="DE"><unparsedAffiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">neutropenia</keyword><keyword xml:id="k2">chemotherapy</keyword><keyword xml:id="k3">granulocyte colony‐stimulating factors</keyword><keyword xml:id="k4">filgrastim</keyword><keyword xml:id="k5">pegfilgrastim</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><!-- Waladkhani A.-R. (2004) European Journal of Cancer Care 13, 371–379
Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia
<p>Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Pegfilgrastim in chemotherapy‐induced neutropenia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title></titleInfo><name type="personal"><namePart type="given">A.‐R.</namePart><namePart type="family">WALADKHANI</namePart><namePart type="termsOfAddress">bsc, phd</namePart><affiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany</affiliation><affiliation>E-mail: waladkha@uni‐trier.de</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Science Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2004-09</dateIssued><edition>Accepted 26 March 2004</edition><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">3</extent><extent unit="references">38</extent><extent unit="words">5291</extent></physicalDescription><abstract lang="en">Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.</abstract><subject lang="en"><genre>keywords</genre><topic>neutropenia</topic><topic>chemotherapy</topic><topic>granulocyte colony‐stimulating factors</topic><topic>filgrastim</topic><topic>pegfilgrastim</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Cancer Care</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0961-5423</identifier><identifier type="eISSN">1365-2354</identifier><identifier type="DOI">10.1111/(ISSN)1365-2354</identifier><identifier type="PublisherID">ECC</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>371</start><end>379</end><total>9</total></extent></part></relatedItem><identifier type="istex">2D0503325A4D3C658F722C331719FB85571CE860</identifier><identifier type="DOI">10.1111/j.1365-2354.2004.00503.x</identifier><identifier type="ArticleID">ECC503</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Science Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001718 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001718 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2D0503325A4D3C658F722C331719FB85571CE860
|texte= Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia
}}
| This area was generated with Dilib version V0.6.31. |  |